Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SmokeyFlu
NCT06841913Phase 4Recruiting
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Sep 2025
- Primary completion
- Dec 2028
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of live attenuated influenza vaccine in influenza (4 arms), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Area Under the Curve of Nasal Mucosal secretome at 7 days, Area Under the Curve of Gene Expression at 7 days and 4 more. Started Sep 2025; status: recruiting.
02
Drugs
live attenuated influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on NCT06841913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06841913.